The purpose of this study is to evaluate the safety and effectiveness of doxorubicin when given with and without an investigational drug called IMC-3G3 in patients with advanced or recurrent soft-tissue sarcoma.
IMC-3G3 is a monoclonal antibody that blocks a protein called platelet-derived growth factor (PDGF) which is often over-active in sarcoma cells. Researchers hope that blocking PDGF will stop tumors from growing.
Doxorubicin is a standard chemotherapy drug that is used to treat sarcoma. Patients in the phase I portion of this study will receive both drugs. Patients in the phase II portion will be randomly assigned to receive doxorubicin with or without IMC-3G3.